Aravive logo
Aravive ARAV
report update icon

Quarterly report 2023-Q3
added 05-16-2026

Aravive Cash Flow 2022-2011 | ARAV

Brief cash flow overview of Aravive

Cash flows are assessed across five available annual periods spanning 2018 to 2022.

Operating cash flow is negative at -$65.1 million, leaving internal funding capacity weak.

Operating cash flow was positive in only 0 of five periods. Cash generation remains unstable.

Overall picture

Aravive's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.

Annual Cash Flow Aravive

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-65.1 M -32.2 M -12.2 M -17.1 M -29.3 M -116 M - - - - - -

Depreciation & Amortization

886 K 974 K 1.83 M 498 K 1.06 M 311 K 215 K 194 K 107 K 17 K 21 K -

Accounts Payables

8.76 M 2.66 M 2.5 M 1.08 M 426 K 1.5 M 1.36 M 1.67 M 1.26 M 315 K - -

All numbers in USD currency

Quarterly Cash Flow Aravive

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-45.2 M -35.4 M -17.8 M - -50.8 M -31.9 M -12.9 M - -23.8 M -15.2 M -10 M - -16.4 M -10.1 M -4.46 M - -12 M -8.61 M -1.4 M - -20.5 M -15.3 M -8.01 M - -79.3 M -56.8 M - - - - - - - - - - - -17.5 M -5.81 M - - -7.17 M -4.71 M - - - - - - - -

Depreciation & Amortization

658 K 436 K 215 K - 664 K 443 K 222 K - 746 K 493 K 240 K - 1.6 M 1.15 M 125 K - 373 K 248 K 126 K - 975 K 236 K 119 K - 190 K 104 K 54 K - 161 K 106 K 53 K - 174 K 113 K 54 K - 59 K 18 K 5 K - 12 K 11 K 5 K - - - - - - - -

Accounts Payables

5.42 M 3.89 M 9.79 M 8.76 M 8.82 M 4.7 M 4.25 M 2.66 M 1.99 M 3.6 M 2.94 M 2.5 M 1.69 M 901 K 1.19 M 1.08 M 2.36 M 711 K 1.37 M 426 K 335 K 804 K 809 K 1.5 M 4.23 M 2.55 M 1.58 M 1.36 M 1.7 M 732 K 1.38 M 1.67 M 1.14 M 1.33 M 601 K 1.26 M 244 K 1.1 M 981 K 315 K 315 K 315 K 315 K - - - - - - - -

Accounts Receivables

- - - - 6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Aravive, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA